BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person ImmuneBD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune

BD and Penn Institute for Immunology and Immune Health Collaborate to Advance Immunotherapy through Flow Cytometry

2025/12/18 20:15
4 min read
For feedback or concerns regarding this content, please contact us at crypto.news@mexc.com

BD FACSDiscover™ A8 Cell Analyzer to Enable Investigation of 30+ Cellular Characteristics to Capture Key Biological Insights and Support Planned 1,000-Person Immune Profiling Study

FRANKLIN LAKES, N.J., Dec. 18, 2025 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, today announced a strategic collaboration with the Institute for Immunology and Immune Health (I3H) at the University of Pennsylvania, to advance research in deep human immune profiling and support the development of immune-mediated therapies.

The collaboration includes developing and validating a high-parameter flow cytometry panel that can capture key functional pathways in whole blood, including phosphorylation markers, which provide powerful insight into how single cells respond to drugs or disease states. The panel will support a planned 1,000-patient immune profiling study, in partnership with the Penn Colton Center for Autoimmunity, expected to start this summer. The project will leverage the BD FACSDiscover™ A8 Cell Analyzer, BD Rhapsody™ System, BD reagents, software and informatics, with BD teams managing reagents, instrumentation, and spectral data algorithms, and I3H teams serving as scientific and clinical leads. The team intends to publish a peer-reviewed manuscript describing the results of the study.

“This project demonstrates the power of collaboration between academia and industry,” said Dr. E. John Wherry, PhD, the Richard and Barbara Schiffrin President’s Distinguished Professor, director of the Institute for Immunology and Immune Health at the University of Pennsylvania, and the director of the Colton Consortium for Autoimmunity. “We are bringing together cross-functional experts to transform human immune profiling for maximum impact, enabling deeper insights from our immune cells that could accelerate development of precise medical treatments.”

The collaboration reflects a shared vision of unlocking the power of the human immune system to advance science and health. It is made possible by the BD FACSDiscover™ A8 Cell Analyzer, which is the first cell analyzer featuring breakthrough spectral and real-time cell imaging technologies, and the new BD Horizon™ Chroma solution for dried high-parameter panels. The project supports the commitment of both organizations to contribute to the research community through collaboration and knowledge sharing.

“High-parameter single-cell studies of this kind, once considered infeasible, are increasingly becoming central to better understanding the human immune system,” said Steve Conly, worldwide president of BD Biosciences. “Our ecosystem of industry-leading BD flow cytometers, single-cell systems, reagents, software and informatics, provide a critical missing puzzle piece that can support the important work of organizations like I3H to translate and deliver immunological insights into quantitative, actionable information for discovery and clinical care teams around the world.”

More information is available at bdbiosciences.com.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its more than 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians’ care delivery process, enable laboratory scientists to accurately detect disease and advance researchers’ capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/, X (formerly Twitter) @BDandCo or Instagram @becton_dickinson. 

Contacts:

Media:

Investors:

Fallon McLoughlin

Adam Reiffe

Director, Public Relations

VP, Investor Relations

201.258.0361

201.847.6927

fallon.mcloughlin@bd.com

adam.reiffe@bd.com

Media for Penn Medicine:

Eric Horvath

Associate News Director

Penn Medicine

215-821-4289

Eric.horvath@pennmedicine.upenn.edu

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/bd-and-penn-institute-for-immunology-and-immune-health-collaborate-to-advance-immunotherapy-through-flow-cytometry-302645260.html

SOURCE BD (Becton, Dickinson and Company)

Market Opportunity
FLOW Logo
FLOW Price(FLOW)
$0.03489
$0.03489$0.03489
0.00%
USD
FLOW (FLOW) Live Price Chart
Disclaimer: The articles reposted on this site are sourced from public platforms and are provided for informational purposes only. They do not necessarily reflect the views of MEXC. All rights remain with the original authors. If you believe any content infringes on third-party rights, please contact crypto.news@mexc.com for removal. MEXC makes no guarantees regarding the accuracy, completeness, or timeliness of the content and is not responsible for any actions taken based on the information provided. The content does not constitute financial, legal, or other professional advice, nor should it be considered a recommendation or endorsement by MEXC.

You May Also Like

Shiba Inu Shibariumscan Hits 45% Indexing Progress

Shiba Inu Shibariumscan Hits 45% Indexing Progress

The post Shiba Inu Shibariumscan Hits 45% Indexing Progress appeared on BitcoinEthereumNews.com. Shiba Inu’s ecosystem is showing steady technical progress as infrastructure
Share
BitcoinEthereumNews2026/03/18 04:30
The Role of Reference Points in Achieving Equilibrium Efficiency in Fair and Socially Just Economies

The Role of Reference Points in Achieving Equilibrium Efficiency in Fair and Socially Just Economies

This article explores how a simple change in the reference point can achieve a Pareto-efficient equilibrium in both free and fair economies and those with social justice.
Share
Hackernoon2025/09/17 22:30
One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight

One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight

The post One Of Frank Sinatra’s Most Famous Albums Is Back In The Spotlight appeared on BitcoinEthereumNews.com. Frank Sinatra’s The World We Knew returns to the Jazz Albums and Traditional Jazz Albums charts, showing continued demand for his timeless music. Frank Sinatra performs on his TV special Frank Sinatra: A Man and his Music Bettmann Archive These days on the Billboard charts, Frank Sinatra’s music can always be found on the jazz-specific rankings. While the art he created when he was still working was pop at the time, and later classified as traditional pop, there is no such list for the latter format in America, and so his throwback projects and cuts appear on jazz lists instead. It’s on those charts where Sinatra rebounds this week, and one of his popular projects returns not to one, but two tallies at the same time, helping him increase the total amount of real estate he owns at the moment. Frank Sinatra’s The World We Knew Returns Sinatra’s The World We Knew is a top performer again, if only on the jazz lists. That set rebounds to No. 15 on the Traditional Jazz Albums chart and comes in at No. 20 on the all-encompassing Jazz Albums ranking after not appearing on either roster just last frame. The World We Knew’s All-Time Highs The World We Knew returns close to its all-time peak on both of those rosters. Sinatra’s classic has peaked at No. 11 on the Traditional Jazz Albums chart, just missing out on becoming another top 10 for the crooner. The set climbed all the way to No. 15 on the Jazz Albums tally and has now spent just under two months on the rosters. Frank Sinatra’s Album With Classic Hits Sinatra released The World We Knew in the summer of 1967. The title track, which on the album is actually known as “The World We Knew (Over and…
Share
BitcoinEthereumNews2025/09/18 00:02